Therapeutic alternatives for COVID-19
DOI:
https://doi.org/10.24265/horizmed.2020.v20n2.13Keywords:
Coronavirus infections, Treatment, TherapyAbstract
In December 2019, China became the center of a pneumonia outbreak of unknown cause that caught the world’s attention. It was the new coronavirus 2019 (2019-nCoV or SARS-CoV-2), which has rapidly spread to the rest of the world. As of March 31, 2020, around 800,000 cases and 38,714 deaths have been reported worldwide. In Peru, 950 cases and 24 deaths have been reported. The virus has been found to affect most frequently elderly people, immunocompromised individuals or those with comorbidities. In this review article, we offer a comprehensive overview of current knowledge related to therapeutic alternatives for COVID-19, from drugs with proven antiviral activity that have been regularly used in other pathologies (arbidol, remdesivir, lopinavir/ritonavir, favipiravir) to drugs that have been usually used as antiparasitic (chloroquine and hydroxychloroquine) or antibacterial agents (teicoplanin and azithromycin), but nowadays have gained notoriety because of their possible and potential efficacy against COVID-19. Likewise, the therapeutic schemes recently included in the technical standard issued by the Ministry of Health of Peru (chloroquine, hydroxychloroquine and hydroxychloroquine/azithromycin) are highlighted. Although significant advances have been achieved in determining potential therapeutic alternatives, randomized controlled trials are needed to determine the safety and efficacy of medications for the treatment of patients with COVID-19.
Downloads
References
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38(1): 10-8.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet Lond Engl. 2020; 395(10223): 470-3.
Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-6.
Johns Hopkins University-Medicine. Coronavirus Resource Center [internet]; 2020. Disponible en: https://coronavirus.jhu.edu/map.html
Wujtewicz M, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S,Piwowarczyk S, Owczuk R. COVID-19- what should anaethesiologists and intensivists know about it?. Anaesthesiol Intensive Ther. 2020; 52(1): 34-41.
Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: a systematic review. Indian J Pharmacol. 2020; 52(1): 56-65.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14(1): 64-8.
Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status. Mil Med Res. 2020; 7(1): 11.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-71.
Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020; 83(3): 217-20.
Holshue ML, De Bolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10): 929-36.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3): 14950.
Yao T-T, Qian J-D, Zhu W-Y, Wang Y, Wang G-Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus: a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020.
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected Pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020; 35(6): e79.
Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. 2020.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1): 58-60.
Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85-94.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93(7): 449-63.
Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. Int J Antimicrob Agents. 2020; 105944.
Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit Cathepsin L in the late endosome/ lysosome and block the entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016; 291(17): 9218-32.
Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv. 2020.
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 105938.
Wang P, Cheng Y. Increasing host cellular Receptor-AngiotensinConverting Enzyme 2 (ACE2) expression by Coronavirus may facilitate 2019-nCoV Infection. BioRxiv. 2020.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.
Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001; 184(6): 770-6.
Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against Coronavirus Disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020; 105945.
Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020.
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 105949.
Resolución Ministerial N° 139-2020-MINSA [internet]. Documento Técnico: Prevención y atención de personas afectadas por COVID-19 en el Perú. Disponible en: https://www.gob.pe/institucion/minsa/normas-legales/465962-139-2020-minsa
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Arturo Pareja Cruz, Julio César Luque Espino
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
